|
Delayed
Hong Kong S.E.
11:53:15 30/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 7.985 HKD | -0.68% |
|
-4.37% | -5.34% |
| 10-28 | CSPC Pharmaceutical Begins Phase 1 Trial of Tumor Drug in China | MT |
| 10-27 | CSPC Pharma Presents Results of Tumor Drug Studies at ESMO Congress 2026 | MT |
Company Valuation: CSPC Pharmaceutical Group Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 100,932 | 97,707 | 86,022 | 55,169 | 96,380 | 91,785 | - | - |
| Change | - | -3.19% | -11.96% | -35.87% | 74.7% | -4.77% | - | - |
| Enterprise Value (EV) 1 | 89,633 | 86,241 | 72,284 | 46,931 | 86,710 | 80,564 | 77,493 | 74,350 |
| Change | - | -3.79% | -16.18% | -35.07% | 84.76% | -7.09% | -3.81% | -4.06% |
| P/E | 14.7x | 14.1x | 13.5x | 12.1x | 21.8x | 9.05x | 13.3x | 12.5x |
| PBR | 3.17x | 2.86x | 2.39x | 1.62x | 2.56x | 2.05x | 1.91x | 1.77x |
| PEG | - | 14.13x | -1.73x | -0.5x | -9.88x | 0x | -0.4x | 1.89x |
| Capitalization / Revenue | 2.94x | 2.77x | 2.52x | 1.78x | 3.26x | 2.38x | 2.57x | 2.43x |
| EV / Revenue | 2.61x | 2.44x | 2.12x | 1.51x | 2.94x | 2.09x | 2.17x | 1.97x |
| EV / EBITDA | 9.5x | 9.43x | 8.39x | 6.22x | 12.1x | 5.87x | 8.09x | 6.96x |
| EV / EBIT | 10.7x | 10.8x | 9.77x | 7.68x | 15.6x | 6.61x | 9.63x | 8.78x |
| EV / FCF | 23.7x | 14.1x | 26.2x | 17.5x | 19.5x | 10.5x | 11.7x | 10.8x |
| FCF Yield | 4.22% | 7.11% | 3.82% | 5.71% | 5.12% | 9.48% | 8.57% | 9.29% |
| Dividend per Share 2 | 0.18 | 0.21 | 0.28 | 0.26 | 0.29 | 0.4601 | 0.3685 | 0.3917 |
| Rate of return | 2.13% | 2.56% | 3.86% | 5.44% | 3.44% | 5.72% | 4.58% | 4.87% |
| EPS 2 | 0.5773 | 0.5831 | 0.5376 | 0.3946 | 0.3859 | 0.8886 | 0.6025 | 0.6425 |
| Distribution rate | 31.2% | 36% | 52.1% | 65.9% | 75.2% | 51.8% | 61.2% | 61% |
| Net sales 1 | 34,309 | 35,292 | 34,175 | 31,046 | 29,533 | 38,487 | 35,696 | 37,829 |
| EBITDA 1 | 9,431 | 9,148 | 8,615 | 7,547 | 7,168 | 13,729 | 9,585 | 10,681 |
| EBIT 1 | 8,366 | 7,952 | 7,400 | 6,113 | 5,564 | 12,184 | 8,044 | 8,472 |
| Net income 1 | 6,901 | 6,949 | 6,382 | 4,632 | 4,409 | 10,145 | 7,019 | 7,511 |
| Net Debt 1 | -11,298 | -11,467 | -13,738 | -8,238 | -9,670 | -11,221 | -14,292 | -17,435 |
| Reference price 2 | 8.470 | 8.200 | 7.260 | 4.780 | 8.430 | 8.040 | 8.040 | 8.040 |
| Nbr of stocks (in thousands) | 11,916,370 | 11,915,520 | 11,848,756 | 11,541,665 | 11,433,025 | 11,416,025 | - | - |
| Announcement Date | 22/3/22 | 22/3/23 | 20/3/24 | 28/3/25 | 25/3/26 | - | - | - |
1HKD in Million2HKD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 8.97x | 2.07x | 5.81x | 5.77% | 11.6B | |
| 37.84x | 13.27x | 28.43x | 0.53% | 1,148B | |
| 39.67x | 6.67x | 18.75x | 1.97% | 652B | |
| 37.4x | 8.39x | 17.35x | 2.4% | 505B | |
| 21.45x | 5.21x | 12.93x | 2.51% | 384B | |
| 102.73x | 5.76x | 24.72x | 2.42% | 348B | |
| 21.89x | 5.76x | 13.88x | 2.85% | 294B | |
| 22.21x | 4.49x | 12.82x | 1.97% | 264B | |
| 28.66x | 7.33x | 13.12x | 2.23% | 244B | |
| -45.79x | 7.11x | 27.55x | 2.07% | 197B | |
| Average | 27.50x | 6.61x | 17.54x | 2.47% | 404.88B | |
| Weighted average by Cap. | 35.21x | 8.38x | 20.60x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 1093 Stock
- Valuation CSPC Pharmaceutical Group Limited
Select your edition
All financial news and data tailored to specific country editions
